CTNM
Contineum Therapeutics, Inc.
Latest Form 4:Sale$40KbyStengone Carmine N. (CEO and President) · filed Aug 3, 2026
Contineum Therapeutics, Inc. (CTNM) has 21 SEC Form 4 filings (49 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Aug 3, 2026.
The most active filer is Chief Scientific Officer Lorrain Daniel S. with 15 filings. Insiders have net sold $1.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Carmine N. Stengone
- Employees:41
- HQ:San Diego, CA, US
- IPO:2024-04-05
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.8M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$531.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| CEO and President | Sale | 2,500 | $40K | Aug 3 | SEC ↗ | |
| Chief Scientific Officer | Sale | 1,015 | $16K | Jul 10 | SEC ↗ | |
| Chief Scientific Officer | Sale | 25 | $400 | Jul 10 | SEC ↗ | |
| CEO and President | Sale | 2,500 | $40K | Jul 8 | SEC ↗ | |
| Chief Scientific Officer | Sale | 28,826 | $462K | Jul 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,353 | $132K | Jul 2 | SEC ↗ | |
Watkins TimFirst in 4 months | CMO & Head of Development | Sale | 10,833 | $174K | Jul 1 | SEC ↗ |
Stengone Carmine N.First in 4 months | CEO and President | Sale | 10,000 | $160K | Jul 1 | SEC ↗ |
| Chief Scientific Officer | Sale | 4,170 | $55K | Jun 1 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $55K | May 1 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $56K | Apr 6 | SEC ↗ | |
| CMO & Head of Development | Sale | 3,611 | $54K | Mar 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $63K | Mar 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,300 | $69K | Feb 26 | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,824 | $61K | Feb 26 | SEC ↗ | |
| CEO and President | Sale | 4,400 | $70K | Feb 26 | SEC ↗ | |
| CEO and President | Sale | 2,700 | $43K | Feb 26 | SEC ↗ | |
| Chief Scientific Officer | Sale | 100 | $2K | Feb 20 | SEC ↗ | |
| Chief Scientific Officer | Sale | 400 | $6K | Feb 13 | SEC ↗ | |
Stengone Carmine N.First filing | CEO and President | Sale | 400 | $6K | Feb 13 | SEC ↗ |
| Chief Scientific Officer | Sale | 4,170 | $62K | Feb 5 | SEC ↗ | |
| CMO & Head of Development | Sale | 3,611 | $51K | Jan 30 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $44K | Jan 6 | SEC ↗ | |
Watkins TimFirst filing | CMO & Head of Development | Sale | 3,611 | $44K | Dec 30 | SEC ↗ |
Lorrain Daniel S.First filing | Chief Scientific Officer | Sale | 4,170 | $51K | Dec 30 | SEC ↗ |
Related companies
Contineum Therapeutics, Inc. is in the Healthcare sector.